Natural products in drug discovery: advances and opportunities

Atanas G. Atanasov(University of Vienna), Sergey B. Zotchev(University of Vienna), Verena M. Dirsch(University of Vienna), the International Natural Product Sciences Taskforce(Gazi University), İlkay Erdoğan Orhan(Polish Mother’s Memorial Hospital Research Institute), Maciej Banach(University of Vienna), Judith M. Rollinger(University of Messina), Davide Barreca(University of Vienna), Wolfram Weckwerth(University of Graz), Rudolf Bauer(Weizmann Institute of Science), Edward A. Bayer(Sami Labs (India)), Muhammed Majeed(Lake Erie College of Osteopathic Medicine), Anupam Bishayee(University of Graz), Valery N. Bochkov(Universität Innsbruck), Günther K. Bonn(UNSW Sydney), Nady Braidy(University of Graz), Franz Bučar(Instituto de Investigación en Ciencias de la Alimentación), Alejandro Cifuentes(Casa Sollievo della Sofferenza), Grazia D’Onofrio(Evotec (United Kingdom)), Michael J. Bodkin(Seoul National University), Marc Diederich(University of Dundee), Albena T. Dinkova‐Kostova(Johannes Gutenberg University Mainz), Thomas Efferth, Khalid El Bairi, Nicolas Arkells(University of Cambridge), Tai-Ping Fan(University of Freiburg), Bernd L. Fiebich(Medical University of Vienna), Michael Freissmuth(Bulgarian Academy of Sciences), Milen I. Georgiev(University College London), Simon Gibbons(University Hospital Southampton NHS Foundation Trust), Keith M. Godfrey(Medical University of Vienna), Christian W. Gruber(UCB Pharma (United Kingdom)), Jag Heer(Innsbruck Medical University), Lukas A. Huber(Instituto de Investigación en Ciencias de la Alimentación), Elena Ibáñez(Universidade do Porto), Anake Kijjoa(Medical University of Warsaw), Anna K. Kiss(Hong Kong Baptist University), Aiping Lü(Universidad de Cádiz), Francisco A. Macı́as, Mark J.S. Miller(Iuliu Hațieganu University of Medicine and Pharmacy), Andrei Mocan(Helmholtz Centre for Infection Research), Rolf Müller(University of Catania), Ferdinando Nicoletti(The University of Texas at San Antonio), George Perry(University of Catania), Valeria Pittalà(University of Salerno), Luca Rastrelli(ETH Zurich), Michael Ristow(Institute of Food Science), Gian Luigi Russo(Instituto Nacional de Investigação Agrária e Veterinária), A. Sanches‐Silva(Paracelsus Medical University), Daniela Schuster(Trinity College Dublin), Helen Sheridan(Medical University of Lublin), Krystyna Skalicka‐Woźniak(National and Kapodistrian University of Athens), Léandros Skaltsounis(Universidade de Santiago de Compostela), Eduardo Sobarzo‐Sánchez(Janssen (United States)), David S. Bredt(Universität Innsbruck), Hermann Stuppner(Health Research Institute of the Balearic Islands), Antoni Sureda(Bulgarian Academy of Sciences), Nikolay Tzvetkov(Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies), Rosa Anna Vacca(Inflammation Research Foundation), Bharat B. Aggarwal(Marche Polytechnic University), Maurizio Battino(Marche Polytechnic University), Francesca Giampieri(Heidelberg University), Michaël Wink(University of Geneva), Jean‐Luc Wolfender(Jiangsu University), Jianbo Xiao(University of Hong Kong), Andy Wai Kan Yeung(Inserm), Gérard Lizard(Bionorica (Germany)), Michael Popp(University College London), Michael Heinrich(Iuliu Hațieganu University of Medicine and Pharmacy), Ioana Berindan-Neagoe(German Center for Infection Research), Marc Stadler(Jiangsu University), Maria Daglia(Leiden University), Robert Verpoorte(University of Florence), Claudiu T. Supuran(University of Florence)
Nature Reviews Drug Discovery
January 28, 2021
10.1038/s41573-020-00114-z
Cited by 4,903Open Access
Full Text

Abstract

Natural products and their structural analogues have historically made a major contribution to pharmacotherapy, especially for cancer and infectious diseases. Nevertheless, natural products also present challenges for drug discovery, such as technical barriers to screening, isolation, characterization and optimization, which contributed to a decline in their pursuit by the pharmaceutical industry from the 1990s onwards. In recent years, several technological and scientific developments - including improved analytical tools, genome mining and engineering strategies, and microbial culturing advances - are addressing such challenges and opening up new opportunities. Consequently, interest in natural products as drug leads is being revitalized, particularly for tackling antimicrobial resistance. Here, we summarize recent technological developments that are enabling natural product-based drug discovery, highlight selected applications and discuss key opportunities.

Related Papers

No related papers found

Powered by citation graph analysis